Thompson Siegel & Walmsley LLC Cuts Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Thompson Siegel & Walmsley LLC decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 9.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 347,809 shares of the medical equipment provider's stock after selling 37,447 shares during the quarter. Thompson Siegel & Walmsley LLC owned 0.17% of Zimmer Biomet worth $36,739,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of ZBH. Atria Investments Inc lifted its position in Zimmer Biomet by 60.2% in the 3rd quarter. Atria Investments Inc now owns 5,429 shares of the medical equipment provider's stock worth $586,000 after buying an additional 2,041 shares during the last quarter. Covestor Ltd lifted its position in Zimmer Biomet by 36.3% in the 3rd quarter. Covestor Ltd now owns 1,088 shares of the medical equipment provider's stock worth $117,000 after buying an additional 290 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet in the 3rd quarter worth approximately $28,000. Oppenheimer & Co. Inc. lifted its position in Zimmer Biomet by 8.6% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 24,995 shares of the medical equipment provider's stock worth $2,698,000 after buying an additional 1,977 shares during the last quarter. Finally, ICICI Prudential Asset Management Co Ltd lifted its position in Zimmer Biomet by 4.6% in the 3rd quarter. ICICI Prudential Asset Management Co Ltd now owns 84,999 shares of the medical equipment provider's stock worth $9,176,000 after buying an additional 3,700 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Remove Ads

Zimmer Biomet Stock Up 1.7 %

ZBH stock traded up $1.88 during midday trading on Monday, hitting $111.85. The stock had a trading volume of 2,435,740 shares, compared to its average volume of 1,474,572. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The firm has a market cap of $22.26 billion, a price-to-earnings ratio of 25.13, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The business has a 50-day moving average of $105.83 and a two-hundred day moving average of $106.92. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the company earned $2.20 EPS. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's dividend payout ratio is 21.57%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several recent research reports. Barclays lowered their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. Stifel Nicolaus boosted their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. JMP Securities reiterated a "market outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Raymond James lowered their price objective on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Finally, Truist Financial reiterated a "hold" rating and issued a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of "Hold" and an average target price of $124.15.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.